Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
复制标题
DOI：
10.2967/jnumed.108.052373
复制
发表时间：
2008-10
期刊：
影响因子：
--
通讯作者：
Pacak K
中科院分区：
文献类型：
--
作者：
Ilias I;Chen CC;Carrasquillo JA;Whatley M;Ling A;Lazúrová I;Adams KT;Perera S;Pacak K
我们比较了非转移性和转移性嗜铬细胞瘤(PHEO)的功能成像方法，包括正电子发射断层扫描(PET)和[123I]-间碘苯基胍([123I]-MIBG)，以及生长抑素受体闪烁成像(SRS)和[111In]-戊四核苷酸(Octreoscan)。方法：我们研究了25名男性和28名女性(平均年龄±SD：44.2±14.2岁)，均经生化证实为非转移性PHEO(n：17)或转移性PHEO(n：36)。评估包括计算机断层扫描(CT)和/或磁共振成像(MRI)的解剖成像，以及至少包括两种核医学模式的功能成像：[18F]-DA PET、[123I]-MIBG闪烁成像或SRS。在每个患者和每个区域的基础上评估功能成像与解剖成像的敏感度。在这个可用队列中，以每个患者为基础，总体敏感度(结合非转移性和转移性PHEO)对[18F]-DA PET、[123I]-MIBG和SRS分别为90.2%、76.0%和22.0%。在每个地区的基础上，总的敏感性是75.4%的[18F]-DA PET，63.4%的[123I]-MIBG，和64.0%的SRS。如果可行，[18F]-DA PET应用于PHEO的评估，因为它比[123I]-MIBG或SRS更敏感。如果没有[18F]-DA PET，[123I]-MIBG显像(对于非转移性/肾上腺PHEO)和SRS(对于转移性PHEO)应该是首选的替代成像方法。
We compared functional imaging modalities including positron emission tomography (PET) with 6-[18F]-fluorodopamine ([18F]-DA) against [123I]-metaiodobenzylguanidine ([123I]-MIBG) and somatostatin receptor scintigraphy (SRS) with [111In]-pentetreotide (Octreoscan) in non-metastatic and metastatic pheochromocytoma (PHEO). Methods: We studied 25 men and 28 women (mean age±SD: 44.2±14.2 years) with biochemically-proven non-metastatic (n: 17) or metastatic (n: 36) PHEO. Evaluation included anatomical imaging with computed tomography (CT) and/or magnetic resonance imaging (MRI) and functional imaging that included at least two nuclear medicine modalities: [18F]-DA PET, [123I]-MIBG scintigraphy, or SRS. Sensitivity of functional imaging vs. anatomical imaging was assessed on a per-patient and on a per-region basis. For this available cohort, on a per patient basis, overall sensitivity (combined for non-metastatic and metastatic PHEO) was 90.2% for [18F]-DA PET, 76.0% for [123I]-MIBG scintigraphy, and 22.0% for SRS. On a per-region basis, overall sensitivity was 75.4% for [18F]-DA PET, 63.4% for [123I]-MIBG scintigraphy, and 64.0% for SRS. If available, [18F]-DA PET should be used in the evaluation of PHEO, since it is more sensitive than [123I]-MIBG scintigraphy or SRS. If [18F]-DA PET is not available, [123I]-MIBG scintigraphy (for non-metastatic/adrenal PHEO) and SRS (for metastatic PHEO) should be the first alternative imaging methods to be used.
登录
查看更多内容
影响因子：
1.5
作者：
Mamede, M;Carrasquillo, JA;Pacak, K
通讯作者：
Pacak, K
影响因子：
19.7
作者：
Hoegerle, S;Nitzsche, E;Neumann, HPH
通讯作者：
Neumann, HPH
影响因子：
20.3
作者：
BRAVO, EL
通讯作者：
BRAVO, EL
影响因子：
10.6
作者：
Fujita, A;Hyodoh, H;Kanazawa, K
通讯作者：
Kanazawa, K
影响因子：
5.8
作者：
Ilias, I;Yu, J;Pacak, K
通讯作者：
Pacak, K